Each state might look a little different, but Medicaid in all states is moving toward some kind of managed care, stated Matt Salo. And a newly proposed rule from CMS regulating access, enrollment, financing and more is an attempt to get everyone on the same page. But some people are concerned that this rule will stifle innovation in the states, Salo said.
People are appropriately distrustful, though, according to Margaret E. O’Kane, MHA, because it’s a new way of doing things and the success of managed care depends on a “vigorous accountability agenda.”
“There’s going to be a lot of pushback from people that are used to working only in fee-for-service and in a different situation,” she said.
Access to care for Medicaid has been a longstanding issue, Austin Frakt, PhD, said, and it remains a complex one because there are a variety of ways to measure access. The new regulations were concerning, in a way, because he found them vague, and that they put a lot of the burden back on states to put a plan in place for standards to measure access to care without specifying what it should look like.
The National Committee for Quality Assurance will be monitoring the situation, O’Kane said, especially since the industry has been in a period of very broad networks, and now the discussion is about narrow networks.
“It’s kind of a new day for us,” she said.
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More